Covered recipient · General Payments record
FENGTING YAN
Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2023 · Entire year
$246,320.64
231 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2023 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $199,012.50 | 50 |
| Travel and Lodging | $21,603.18 | 88 |
| Consulting Fee | $15,490.75 | 6 |
| Food and Beverage | $5,593.86 | 82 |
| Compensation for serving as faculty or as a speaker for a medical education program | $4,290.00 | 1 |
| Honoraria | $318.16 | 3 |
| Education | $12.19 | 1 |
By paying entity
PY2023 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Stemline Therapeutics Inc. | $72,867.22 | 51 |
| Gilead Sciences, Inc. | $45,857.70 | 34 |
| AstraZeneca Pharmaceuticals LP | $42,284.15 | 40 |
| Lilly USA, LLC | $41,163.84 | 74 |
| Seagen Inc. | $25,995.99 | 13 |
| Daiichi Sankyo Inc. | $13,907.80 | 10 |
| Genentech USA, Inc. | $1,977.02 | 4 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $1,942.25 | 3 |
| TerSera Therapeutics LLC | $217.00 | 1 |
| Genentech, Inc. | $107.67 | 1 |
Page 2 of 5; records 51–100 of 231 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
FENGTING YAN
NPI 1427319334 · CMS profile ID 603232
Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology
SEATTLE, WA
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 5; records 51–100 of 231 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1427319334?year=2023&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- FENGTING YAN, NPI 1427319334, CMS profile ID 603232. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 5; records 51–100 of 231 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1427319334?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
- APA 7
- IndustryPayments. (2026). FENGTING YAN, NPI 1427319334, CMS profile ID 603232. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 5; records 51–100 of 231 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1427319334?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
- Bluebook
- FENGTING YAN, NPI 1427319334, CMS profile ID 603232, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 5; records 51–100 of 231 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1427319334?year=2023&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2023
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30
231 matching records · $246,320.64 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–100 of 231.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Daiichi Sankyo Inc. | $4,100.00 | 09/26/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1006597361 | CMS |
| Daiichi Sankyo Inc. | $113.58 | 09/21/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1006615885 | CMS |
| Gilead Sciences, Inc. | $5,140.00 | 09/20/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1035835257 | CMS |
| Gilead Sciences, Inc. | $64.51 | 09/15/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1025495235 | CMS |
| Stemline Therapeutics Inc. | $7,410.00 | 09/15/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1040025721 | CMS |
| Stemline Therapeutics Inc. | $4,290.00 | 09/15/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1040025771 | CMS |
| Gilead Sciences, Inc. | $223.28 | 09/13/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1025495231 | CMS |
| Gilead Sciences, Inc. | $881.62 | 09/13/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1025495233 | CMS |
| Gilead Sciences, Inc. | $120.00 | 09/13/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1025515043 | CMS |
| Stemline Therapeutics Inc. | $4,290.00 | 08/31/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1040025709 | CMS |
| Stemline Therapeutics Inc. | $7,410.00 | 08/31/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1040025813 | CMS |
| Stemline Therapeutics Inc. | $260.66 | 08/31/2023 | Honoraria | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1040025823 | CMS |
| Stemline Therapeutics Inc. | $12.18 | 08/31/2023 | Honoraria | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1040025843 | CMS |
| Stemline Therapeutics Inc. | $4,290.00 | 08/31/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1040025847 | CMS |
| Stemline Therapeutics Inc. | $179.77 | 08/28/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1040025725 | CMS |
| Stemline Therapeutics Inc. | $319.65 | 08/28/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1040025731 | CMS |
| AstraZeneca Pharmaceuticals LP | $124.99 | 08/27/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1015640127 | CMS |
| Stemline Therapeutics Inc. | $166.62 | 08/24/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1040025735 | CMS |
| Stemline Therapeutics Inc. | $106.32 | 08/23/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1040025717 | CMS |
| Stemline Therapeutics Inc. | $227.79 | 08/23/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1040025741 | CMS |
| Genentech, Inc. | $107.67 | 08/22/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1040363371 | CMS |
| Stemline Therapeutics Inc. | $87.64 | 08/02/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1040025701 | CMS |
| Stemline Therapeutics Inc. | $477.75 | 08/02/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1040025713 | CMS |
| Lilly USA, LLC | $119.21 | 07/27/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1031418459 | CMS |
| AstraZeneca Pharmaceuticals LP | $20.81 | 07/25/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1011730975 | CMS |
| Lilly USA, LLC | $79.22 | 07/22/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1031418511 | CMS |
| Gilead Sciences, Inc. | $83.13 | 07/15/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1025526881 | CMS |
| Stemline Therapeutics Inc. | $181.25 | 07/13/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1040025853 | CMS |
| Stemline Therapeutics Inc. | $244.50 | 07/03/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1040025809 | CMS |
| Stemline Therapeutics Inc. | $234.90 | 07/03/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1040025819 | CMS |
| Stemline Therapeutics Inc. | $4,290.00 | 06/30/2023 | Compensation for serving as faculty or as a speaker for a medical education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1040025697 | CMS |
| Stemline Therapeutics Inc. | $244.62 | 06/30/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1040025827 | CMS |
| Daiichi Sankyo Inc. | $17.03 | 06/28/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1006595271 | CMS |
| Daiichi Sankyo Inc. | $2,750.00 | 06/28/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1006595807 | CMS |
| AstraZeneca Pharmaceuticals LP | $5,500.00 | 06/26/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1015249305 | CMS |
| Gilead Sciences, Inc. | $72.40 | 06/25/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1025528355 | CMS |
| Daiichi Sankyo Inc. | $120.11 | 06/22/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1006615423 | CMS |
| Stemline Therapeutics Inc. | $634.80 | 06/22/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1040025833 | CMS |
| AstraZeneca Pharmaceuticals LP | $1,265.09 | 06/21/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1014888537 | CMS |
| AstraZeneca Pharmaceuticals LP | $121.53 | 06/21/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1015335073 | CMS |
| AstraZeneca Pharmaceuticals LP | $30.33 | 06/21/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1015813401 | CMS |
| AstraZeneca Pharmaceuticals LP | $48.14 | 06/21/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1015844815 | CMS |
| AstraZeneca Pharmaceuticals LP | $271.66 | 06/21/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1015988537 | CMS |
| Gilead Sciences, Inc. | $6,720.00 | 06/14/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1035835253 | CMS |
| Gilead Sciences, Inc. | $3,950.00 | 06/13/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1035835245 | CMS |
| Lilly USA, LLC | $75.62 | 06/13/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1031386180 | CMS |
| Lilly USA, LLC | $23.36 | 06/13/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1031418495 | CMS |
| Lilly USA, LLC | $19.87 | 06/13/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1031418499 | CMS |
| Lilly USA, LLC | $28.82 | 06/13/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1031418503 | CMS |
| Lilly USA, LLC | $58.00 | 06/13/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1031418507 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $2,870.00 | 5 |
| PY2025 | Principal investigator | $2,284,918.99 | 97 |
| PY2024 | Recipient | $4,800.00 | 4 |
| PY2024 | Principal investigator | $2,109,058.86 | 121 |
| PY2023 | Principal investigator | $1,760,801.59 | 89 |
| PY2022 | Principal investigator | $608,997.29 | 21 |
| PY2021 | Principal investigator | $23,200.00 | 1 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
102 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | PFIZER INC. | $23,390.72 | 12/30/2025 | Covered Recipient Teaching Hospital SWEDISH ISSAQUAH | A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228815819 |
| Principal investigator 1 | PFIZER INC. | $65,656.72 | 12/25/2025 | Covered Recipient Teaching Hospital SWEDISH ISSAQUAH | A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07248144 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1228815764 |
| Principal investigator 1 | PFIZER INC. | $74.80 | 12/18/2025 | Covered Recipient Teaching Hospital SWEDISH ISSAQUAH | A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228815914 |
| Principal investigator 1 | PFIZER INC. | $86,461.47 | 12/13/2025 | Covered Recipient Teaching Hospital SWEDISH ISSAQUAH | A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228817217 |
| Principal investigator 1 | PFIZER INC. | $131,200.56 | 12/10/2025 | Covered Recipient Teaching Hospital SWEDISH ISSAQUAH | A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07248144 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1228815997 |
| Recipient | PFIZER INC. | $940.00 | 12/09/2025 | Covered Recipient Physician | LADIRATUZUMAB VEDOTIN CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228802595 |
| Principal investigator 1 | PFIZER INC. | $1,171.80 | 11/25/2025 | Covered Recipient Teaching Hospital SWEDISH ISSAQUAH | A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228819002 |
| Principal investigator 1 | PFIZER INC. | $27,498.02 | 11/13/2025 | Covered Recipient Teaching Hospital SWEDISH ISSAQUAH | A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228818354 |
| Principal investigator 1 | PFIZER INC. | $36,514.64 | 11/13/2025 | Covered Recipient Teaching Hospital SWEDISH ISSAQUAH | A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07248144 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1228818990 |
| Principal investigator 1 | PFIZER INC. | $140,745.04 | 11/04/2025 | Covered Recipient Teaching Hospital SWEDISH ISSAQUAH | A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07248144 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1228818996 |
| Principal investigator 1 | PFIZER INC. | $10,000.00 | 10/31/2025 | Non-covered Recipient Entity Pacific Cancer Research Consortium NCORP | THE COMPASSHER2 TRIALS COMPREHENSIVE USE OF PATHOLOGIC RESPONSE ASSESSMENT TO OPTIMIZE THERAPY IN HER2POSITIVE BREAST CANCER COMPASSHER2 RESIDUAL DISEASE RD A DOUBLEBLINDED PHASE III RANDOMIZED TRIAL OF TDM1 COMPARED WITH TDM1 AND TUCATINIB | No dispute reported | 06/30/2026 | 1228721191 |
| Principal investigator 1 | PFIZER INC. | $4,111.56 | 10/23/2025 | Covered Recipient Teaching Hospital SWEDISH ISSAQUAH | A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228826015 |
| Principal investigator 1 | Genentech, Inc. | $14,360.00 | 10/14/2025 | Covered Recipient Teaching Hospital Swedish Issaquah | GIREDESTRANT in 1L HER2 ER mBC patients | No dispute reported | 06/30/2026 | 1211556410 |
| Principal investigator 1 | PFIZER INC. | $25,312.88 | 10/14/2025 | Covered Recipient Teaching Hospital SWEDISH ISSAQUAH | A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228826105 |
| Principal investigator 1 | PFIZER INC. | $178,319.13 | 09/23/2025 | Covered Recipient Teaching Hospital SWEDISH ISSAQUAH | A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228835796 |
| Principal investigator 1 | Genentech, Inc. | $19,294.00 | 09/22/2025 | Covered Recipient Teaching Hospital Swedish Issaquah | GIREDESTRANT in 1L HER2 ER mBC patients | No dispute reported | 06/30/2026 | 1211556406 |
| Principal investigator 1 | PFIZER INC. | $4,867.56 | 09/15/2025 | Covered Recipient Teaching Hospital SWEDISH ISSAQUAH | A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228712016 |
| Principal investigator 1 | PFIZER INC. | $8,112.60 | 09/10/2025 | Covered Recipient Teaching Hospital SWEDISH ISSAQUAH | A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228712018 |
| Principal investigator 1 | PFIZER INC. | $145,468.32 | 09/06/2025 | Covered Recipient Teaching Hospital SWEDISH ISSAQUAH | A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07248144 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1228836554 |
| Principal investigator 1 | Genentech, Inc. | $15,765.00 | 08/27/2025 | Covered Recipient Teaching Hospital Swedish Issaquah | GIREDESTRANT in 1L HER2 ER mBC patients | No dispute reported | 06/30/2026 | 1211556391 |
| Principal investigator 1 | Genentech, Inc. | $76,750.00 | 08/26/2025 | Covered Recipient Teaching Hospital Swedish Issaquah | GIREDESTRANT in 1L HER2 ER mBC patients | No dispute reported | 06/30/2026 | 1211556403 |
| Principal investigator 1 | PFIZER INC. | $5,878.74 | 08/22/2025 | Covered Recipient Teaching Hospital SWEDISH ISSAQUAH | A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228844263 |
| Principal investigator 1 | PFIZER INC. | $1,622.52 | 08/19/2025 | Covered Recipient Teaching Hospital SWEDISH ISSAQUAH | A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228712454 |
| Principal investigator 1 | PFIZER INC. | $38,176.56 | 08/19/2025 | Covered Recipient Teaching Hospital SWEDISH ISSAQUAH | A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07248144 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1228843261 |
| Principal investigator 1 | PFIZER INC. | $3,245.04 | 08/18/2025 | Covered Recipient Teaching Hospital SWEDISH ISSAQUAH | A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228712450 |
| Principal investigator 1 | Genentech, Inc. | $17,950.00 | 08/15/2025 | Covered Recipient Teaching Hospital Swedish Issaquah | GIREDESTRANT in 1L HER2 ER mBC patients | No dispute reported | 06/30/2026 | 1211556398 |
| Principal investigator 1 | PFIZER INC. | $35,773.73 | 08/13/2025 | Covered Recipient Teaching Hospital SWEDISH ISSAQUAH | A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228843251 |
| Principal investigator 1 | PFIZER INC. | $8,112.60 | 08/05/2025 | Covered Recipient Teaching Hospital SWEDISH ISSAQUAH | A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228712452 |
| Principal investigator 1 | PFIZER INC. | $22,573.74 | 07/24/2025 | Covered Recipient Teaching Hospital SWEDISH ISSAQUAH | A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228846874 |
| Principal investigator 1 | PFIZER INC. | $1,622.52 | 07/21/2025 | Covered Recipient Teaching Hospital SWEDISH ISSAQUAH | A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228712014 |
| Principal investigator 1 | PFIZER INC. | $3,245.04 | 07/21/2025 | Covered Recipient Teaching Hospital SWEDISH ISSAQUAH | A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228712516 |
| Principal investigator 1 | PFIZER INC. | $9,735.12 | 07/14/2025 | Covered Recipient Teaching Hospital SWEDISH ISSAQUAH | A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228712638 |
| Principal investigator 1 | PFIZER INC. | $5,536.00 | 07/14/2025 | Covered Recipient Teaching Hospital SWEDISH ISSAQUAH | A RANDOMIZED PHASE II TRIAL OF CIRCULATING TUMOR DNAGUIDED SECOND LINE ADJUVANT THERAPY FOR HIGH RESIDUAL RISK ESTROGEN RECEPTOR POSITIVE HER2 NEGATIVE BREAST CANCER DAREWI251141 | No dispute reported | 06/30/2026 | 1228721481 |
| Principal investigator 1 | PFIZER INC. | $13,829.84 | 07/10/2025 | Covered Recipient Teaching Hospital SWEDISH ISSAQUAH | A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07248144 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1228846882 |
| Recipient | PFIZER INC. | $330.00 | 07/08/2025 | Covered Recipient Physician | ELRANATAMAB CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228802586 |
| Principal investigator 1 | PFIZER INC. | $45,784.80 | 07/02/2025 | Covered Recipient Teaching Hospital SWEDISH ISSAQUAH | A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07248144 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1228847941 |
| Principal investigator 1 | PFIZER INC. | $650.08 | 06/26/2025 | Covered Recipient Teaching Hospital SWEDISH ISSAQUAH | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS FULVESTRANT COMPARED TO INVESTIGATORS CHOICE OF THERAPY IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTORPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR CDK 46 INHIBITOR BASED THERAPY | No dispute reported | 06/30/2026 | 1228851485 |
| Principal investigator 1 | PFIZER INC. | $26,752.71 | 06/26/2025 | Covered Recipient Teaching Hospital SWEDISH ISSAQUAH | A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228851548 |
| Principal investigator 1 | PFIZER INC. | $1,622.51 | 06/25/2025 | Non-covered Recipient Entity Swedish Medical Center | A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228840854 |
| Principal investigator 1 | PFIZER INC. | $305,867.05 | 06/25/2025 | Covered Recipient Teaching Hospital SWEDISH ISSAQUAH | A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228851556 |
| Principal investigator 1 | PFIZER INC. | $1,622.51 | 06/24/2025 | Non-covered Recipient Entity Swedish Medical Center | A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228840413 |
| Principal investigator 1 | PFIZER INC. | $1,622.51 | 06/23/2025 | Non-covered Recipient Entity Swedish Medical Center | A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228840204 |
| Principal investigator 1 | PFIZER INC. | $740.00 | 06/23/2025 | Non-covered Recipient Entity Swedish First Hill | A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07248144 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1228840348 |
| Principal investigator 1 | Genentech, Inc. | $4,959.00 | 06/16/2025 | Covered Recipient Teaching Hospital Swedish Issaquah | GIREDESTRANT in 1L HER2 ER mBC patients | No dispute reported | 06/30/2026 | 1211556374 |
| Principal investigator 1 | PFIZER INC. | $8,112.55 | 06/09/2025 | Non-covered Recipient Entity Swedish Medical Center | A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228840625 |
| Principal investigator 1 | Genentech, Inc. | $5,000.00 | 06/04/2025 | Covered Recipient Teaching Hospital Swedish Issaquah | GIREDESTRANT in 1L HER2 ER mBC patients | No dispute reported | 06/30/2026 | 1211556379 |
| Principal investigator 1 | PFIZER INC. | $1,110.00 | 06/02/2025 | Non-covered Recipient Entity Swedish First Hill | A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07248144 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1228840667 |
| Recipient | PFIZER INC. | $940.00 | 05/30/2025 | Covered Recipient Physician | ELRANATAMAB CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228838739 |
| Principal investigator 1 | PFIZER INC. | $10,519.96 | 05/29/2025 | Covered Recipient Teaching Hospital SWEDISH ISSAQUAH | A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07248144 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1228858940 |
| Principal investigator 1 | PFIZER INC. | $5,053.08 | 05/29/2025 | Covered Recipient Teaching Hospital SWEDISH ISSAQUAH | A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228858946 |
| Principal investigator 1 | PFIZER INC. | $1,622.51 | 05/28/2025 | Non-covered Recipient Entity Swedish Medical Center | A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228840283 |
| Principal investigator 1 | PFIZER INC. | $740.00 | 05/27/2025 | Non-covered Recipient Entity Swedish First Hill | A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07248144 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1228840210 |
| Principal investigator 1 | PFIZER INC. | $27,756.24 | 05/22/2025 | Covered Recipient Teaching Hospital SWEDISH ISSAQUAH | A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07248144 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1228858312 |
| Principal investigator 1 | PFIZER INC. | $18,663.02 | 05/14/2025 | Covered Recipient Teaching Hospital SWEDISH ISSAQUAH | A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228858898 |
| Principal investigator 1 | PFIZER INC. | $11,357.57 | 05/12/2025 | Non-covered Recipient Entity Swedish Medical Center | A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228840888 |
| Principal investigator 1 | PFIZER INC. | $540.00 | 05/09/2025 | Non-covered Recipient Entity Swedish Health Services | A RANDOMIZED PHASE II TRIAL OF CIRCULATING TUMOR DNAGUIDED SECOND LINE ADJUVANT THERAPY FOR HIGH RESIDUAL RISK ESTROGEN RECEPTOR POSITIVE HER2 NEGATIVE BREAST CANCER DAREWI251141 | No dispute reported | 06/30/2026 | 1228845348 |
| Principal investigator 1 | PFIZER INC. | $1,622.51 | 05/05/2025 | Non-covered Recipient Entity Swedish Medical Center | A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228840405 |
| Principal investigator 1 | PFIZER INC. | $48,741.00 | 05/03/2025 | Covered Recipient Teaching Hospital SWEDISH ISSAQUAH | A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228858932 |
| Principal investigator 1 | PFIZER INC. | $97,195.48 | 05/03/2025 | Covered Recipient Teaching Hospital SWEDISH ISSAQUAH | A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07248144 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1228859010 |
| Principal investigator 1 | PFIZER INC. | $185.00 | 04/30/2025 | Non-covered Recipient Entity Swedish First Hill | A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07248144 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1228840453 |
| Principal investigator 1 | PFIZER INC. | $6,490.04 | 04/28/2025 | Non-covered Recipient Entity Swedish Medical Center | A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228840655 |
| Principal investigator 1 | PFIZER INC. | $1,418.00 | 04/25/2025 | Non-covered Recipient Entity Swedish Health Services | A RANDOMIZED PHASE II TRIAL OF CIRCULATING TUMOR DNAGUIDED SECOND LINE ADJUVANT THERAPY FOR HIGH RESIDUAL RISK ESTROGEN RECEPTOR POSITIVE HER2 NEGATIVE BREAST CANCER DAREWI251141 | No dispute reported | 06/30/2026 | 1228845265 |
| Principal investigator 1 | Genentech, Inc. | $11,577.00 | 04/16/2025 | Covered Recipient Teaching Hospital Swedish Issaquah | GIREDESTRANT in 1L HER2 ER mBC patients | No dispute reported | 06/30/2026 | 1211556394 |
| Principal investigator 1 | PFIZER INC. | $2,430.00 | 04/11/2025 | Non-covered Recipient Entity Swedish Health Services | A RANDOMIZED PHASE II TRIAL OF CIRCULATING TUMOR DNAGUIDED SECOND LINE ADJUVANT THERAPY FOR HIGH RESIDUAL RISK ESTROGEN RECEPTOR POSITIVE HER2 NEGATIVE BREAST CANCER DAREWI251141 | No dispute reported | 06/30/2026 | 1228846227 |
| Principal investigator 1 | PFIZER INC. | $18,469.90 | 04/05/2025 | Covered Recipient Teaching Hospital SWEDISH ISSAQUAH | A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228859892 |
| Principal investigator 1 | PFIZER INC. | $29,245.44 | 04/05/2025 | Covered Recipient Teaching Hospital SWEDISH ISSAQUAH | A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07248144 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1228859898 |
| Principal investigator 1 | PFIZER INC. | $9,735.06 | 03/31/2025 | Non-covered Recipient Entity Swedish Medical Center | A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228840650 |
| Principal investigator 1 | PFIZER INC. | $6,490.04 | 03/24/2025 | Non-covered Recipient Entity Swedish Medical Center | A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228840892 |
| Principal investigator 1 | PFIZER INC. | $41,120.96 | 03/21/2025 | Covered Recipient Teaching Hospital SWEDISH ISSAQUAH | A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07248144 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1228862446 |
| Principal investigator 1 | PFIZER INC. | $42,397.48 | 03/21/2025 | Covered Recipient Teaching Hospital SWEDISH ISSAQUAH | A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228862460 |
| Principal investigator 1 | PFIZER INC. | $270.00 | 03/14/2025 | Non-covered Recipient Entity Swedish Health Services | A RANDOMIZED PHASE II TRIAL OF CIRCULATING TUMOR DNAGUIDED SECOND LINE ADJUVANT THERAPY FOR HIGH RESIDUAL RISK ESTROGEN RECEPTOR POSITIVE HER2 NEGATIVE BREAST CANCER DAREWI251141 | No dispute reported | 06/30/2026 | 1228845254 |
| Principal investigator 1 | PFIZER INC. | $6,490.04 | 03/10/2025 | Non-covered Recipient Entity Swedish Medical Center | A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228840217 |
| Principal investigator 1 | PFIZER INC. | $1,295.00 | 03/04/2025 | Non-covered Recipient Entity Swedish First Hill | A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07248144 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1228840458 |
| Principal investigator 1 | PFIZER INC. | $6,531.54 | 03/01/2025 | Covered Recipient Teaching Hospital SWEDISH ISSAQUAH | A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228862454 |
| Principal investigator 1 | PFIZER INC. | $810.00 | 02/28/2025 | Non-covered Recipient Entity Swedish Health Services | A RANDOMIZED PHASE II TRIAL OF CIRCULATING TUMOR DNAGUIDED SECOND LINE ADJUVANT THERAPY FOR HIGH RESIDUAL RISK ESTROGEN RECEPTOR POSITIVE HER2 NEGATIVE BREAST CANCER DAREWI251141 | No dispute reported | 06/30/2026 | 1228845260 |
| Principal investigator 1 | PFIZER INC. | $1,480.00 | 02/26/2025 | Non-covered Recipient Entity Swedish First Hill | A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07248144 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1228840343 |
| Principal investigator 1 | Genentech, Inc. | $18,014.00 | 02/19/2025 | Covered Recipient Teaching Hospital Swedish Issaquah | GIREDESTRANT in 1L HER2 ER mBC patients | No dispute reported | 06/30/2026 | 1211556382 |
| Principal investigator 1 | PFIZER INC. | $9,735.06 | 02/19/2025 | Non-covered Recipient Entity Swedish Medical Center | A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228840289 |
| Principal investigator 1 | PFIZER INC. | $16,225.10 | 02/17/2025 | Non-covered Recipient Entity Swedish Medical Center | A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228840295 |
| Principal investigator 1 | PFIZER INC. | $1,622.51 | 02/17/2025 | Non-covered Recipient Entity Swedish Medical Center | A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228840446 |
| Principal investigator 1 | PFIZER INC. | $1,622.51 | 02/17/2025 | Non-covered Recipient Entity Swedish Medical Center | A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228840671 |
| Principal investigator 1 | PFIZER INC. | $51,733.04 | 02/13/2025 | Covered Recipient Teaching Hospital SWEDISH ISSAQUAH | A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07248144 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1228835886 |
| Principal investigator 1 | PFIZER INC. | $81,985.60 | 02/13/2025 | Covered Recipient Teaching Hospital SWEDISH ISSAQUAH | A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228836547 |
| Principal investigator 1 | PFIZER INC. | $1,372.24 | 02/05/2025 | Covered Recipient Teaching Hospital SWEDISH ISSAQUAH | AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07220060 PLUS FULVESTRANT COMPARED TO INVESTIGATORS CHOICE OF THERAPY IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTORPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR CDK 46 INHIBITOR BASED THERAPY | No dispute reported | 06/30/2026 | 1228835891 |
| Principal investigator 1 | PFIZER INC. | $555.00 | 02/05/2025 | Non-covered Recipient Entity Swedish First Hill | A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07248144 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1228840620 |
| Principal investigator 1 | PFIZER INC. | $10,000.00 | 02/03/2025 | Non-covered Recipient Entity Montana Cancer Consortium | THE COMPASSHER2 TRIALS COMPREHENSIVE USE OF PATHOLOGIC RESPONSE ASSESSMENT TO OPTIMIZE THERAPY IN HER2POSITIVE BREAST CANCER COMPASSHER2 RESIDUAL DISEASE RD A DOUBLEBLINDED PHASE III RANDOMIZED TRIAL OF TDM1 COMPARED WITH TDM1 AND TUCATINIB | No dispute reported | 06/30/2026 | 1228842448 |
| Principal investigator 1 | PFIZER INC. | $1,418.00 | 01/30/2025 | Non-covered Recipient Entity Swedish Health Services | A RANDOMIZED PHASE II TRIAL OF CIRCULATING TUMOR DNAGUIDED SECOND LINE ADJUVANT THERAPY FOR HIGH RESIDUAL RISK ESTROGEN RECEPTOR POSITIVE HER2 NEGATIVE BREAST CANCER DAREWI251141 | No dispute reported | 06/30/2026 | 1228846218 |
| Principal investigator 1 | PFIZER INC. | $270.00 | 01/30/2025 | Non-covered Recipient Entity Swedish Health Services | A RANDOMIZED PHASE II TRIAL OF CIRCULATING TUMOR DNAGUIDED SECOND LINE ADJUVANT THERAPY FOR HIGH RESIDUAL RISK ESTROGEN RECEPTOR POSITIVE HER2 NEGATIVE BREAST CANCER DAREWI251141 | No dispute reported | 06/30/2026 | 1228846236 |
| Recipient | PFIZER INC. | $330.00 | 01/28/2025 | Covered Recipient Physician | MAVELERTINIB CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228838620 |
| Recipient | PFIZER INC. | $330.00 | 01/28/2025 | Covered Recipient Physician | MAVELERTINIB CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228839524 |
| Principal investigator 1 | PFIZER INC. | $3,297.05 | 01/24/2025 | Covered Recipient Teaching Hospital SWEDISH ISSAQUAH | A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228863654 |
| Principal investigator 1 | PFIZER INC. | $2,093.04 | 01/24/2025 | Covered Recipient Teaching Hospital SWEDISH ISSAQUAH | A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07248144 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1228863673 |
| Principal investigator 1 | PFIZER INC. | $325.00 | 01/20/2025 | Non-covered Recipient Entity Swedish Medical Center | A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228840401 |
| Principal investigator 1 | Genentech, Inc. | $21,179.00 | 01/17/2025 | Covered Recipient Teaching Hospital Swedish Issaquah | GIREDESTRANT in 1L HER2 ER mBC patients | No dispute reported | 06/30/2026 | 1211556386 |
| Principal investigator 1 | PFIZER INC. | $1,625.00 | 01/15/2025 | Non-covered Recipient Entity Swedish Medical Center | A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228840633 |
| Principal investigator 1 | PFIZER INC. | $325.00 | 01/14/2025 | Non-covered Recipient Entity Swedish Medical Center | A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228840644 |
| Principal investigator 1 | PFIZER INC. | $18,919.99 | 01/14/2025 | Covered Recipient Teaching Hospital SWEDISH ISSAQUAH | A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228863659 |
| Principal investigator 1 | PFIZER INC. | $25,490.48 | 01/14/2025 | Covered Recipient Teaching Hospital SWEDISH ISSAQUAH | A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07248144 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1228863683 |
| Principal investigator 1 | PFIZER INC. | $555.00 | 01/13/2025 | Non-covered Recipient Entity Swedish First Hill | A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07248144 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1228840675 |
| Principal investigator 1 | PFIZER INC. | $325.00 | 01/13/2025 | Non-covered Recipient Entity Swedish Medical Center | A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228840896 |
| Principal investigator 1 | PFIZER INC. | $325.00 | 01/07/2025 | Non-covered Recipient Entity Swedish Medical Center | A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228840354 |
| Principal investigator 1 | PFIZER INC. | $19,439.51 | 01/03/2025 | Covered Recipient Teaching Hospital SWEDISH ISSAQUAH | A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1228863646 |